Liu Wei Di Huang Wan, a well-known traditional Chinese medicine, induces CYP1A2 while suppressing CYP2A6 and N-acetyltransferase 2 activities in man

Journal of Ethnopharmacology

Volumn 132, Issue 1, 2010, Pages 213-218

  Chen, Yao ^a   Kang, Zhen ^b   Yan, Jin ^a   Yang, Guo Ping ^a   Tan, Zhi Rong ^a   Zhou, Gan ^a   Ouyang, Dong Sheng ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b HUNAN CHILDREN'S HOSPITAL   (China)

Author keywords

CYP1A2; CYP2A6; Liu Wei Di Huang Wan; N acetyltransferase 2; Xanthine oxidase

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; CAFFEINE; CHINESE DRUG; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; LIU WEI DI HUANG WAN; PLACEBO; UNCLASSIFIED DRUG; XANTHINE OXIDASE;

ADULT; ARTICLE; DRUG EFFECT; DRUG EXCRETION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; HUMAN; HUMAN EXPERIMENT; IN VIVO CULTURE; MALE; NORMAL HUMAN;

ADULT; ARYL HYDROCARBON HYDROXYLASES; ARYLAMINE N-ACETYLTRANSFERASE; CAFFEINE; CHINA; CYTOCHROME P-450 CYP1A2; DRUGS, CHINESE HERBAL; ENZYME INDUCTION; HUMANS; MALE; METABOLIC DETOXICATION, DRUG; YOUNG ADULT;

EID: 77957812078     PISSN: 03788741     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jep.2010.08.011     Document Type: Article

References (22)

1. Begas E., Kouvaras E., Tsakalof A., Papakosta S., Asprodini E.K. In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios. Biomedical Chromatography 2007, 21:190-200.
2. Butler M.A., Lang N.P., Young J.F., Caporaso N.E., Vineis P., Hayes R.B., Teitel C.H., Massengill J.P., Lawsen M.F., Kadlubar F.F. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992, 2:116-127.
3. Campbell M.E., Spielberg S.P., Kalow W. A urinary metabolite ratio that reflects systemic caffeine clearance. Clinical Pharmacology and Therapeutics 1987, 42:157-165.
4. Cheng J.T., Liu I.M., Chi T.C., Su H.C., Chang C.G. Stimulation of insulin release in rats by Die-Huang-Wan, a herbal mixture used in Chinese traditional medicine. Journal of Pharmacy and Pharmacology 2001, 53:273-276.
5. Desbrow B, Hughes R., Leveritt M., Scheelings P. An examination of consumer exposure to caffeine from retail coffee outlets. Food and Chemical Toxicology 2007, 45:1588-1592.
6. Dupret J.M., Rodrigues-Lima F. Structure and regulation of the drug-metabolizing enzymes arylamine N-acetyltransferases. Current Medicinal Chemistry 2005, 12:311-318.
7. Eugster H.P., Sengstag C. Caffeine, estradiol and progesterone interact with human CYP1A1 and CYP1A2. Evidence from cDNA-directed expression in Saccharomyces cerevisiae. Drug Metabolism and Disposition 1993, 21:43-49.
8. Grant D.M., Tang B.K., Kalow W. Variability in caffeine metabolism. Clinical Pharmacology and Therapeutics 1983, 33:591-602.
9. Hsieh M.T., Cheng S.J., Lin L.W., Wang W.H., Wu C.R. The ameliorating effects of acute and chronic administration of Liu Wei Di Huang Wan on learning performance in rodents. Biological & Pharmaceutical Bulletin 2003, 26:156-161.
10. Ishibe N., Sinha R., Hein D.W., Kulldorff M., Strickland P., Fretland A.J., Chow W.H., Kadlubar F.F., Lang N.P., Rothman N. Genetic polymorphisms in heterocyclic amine metabolism and risk of colorectal adenomas. Pharmacogenetics 2002, 12:145-150.
11. Krul C., Hageman G. Analysis of urinary caffeine metabolites to assess biotransformation enzyme activities by reversed-phase high-performance liquid chromatography. Journal of Chromatography B: Biomedical Sciences 1998, 709:27-34.
12. Malaiyandi V., Goodz S.D., Sellers E.M., Tyndale R.F. CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking. Cancer Epidemiology, Biomarkers & Prevention 2006, 15:1812-1819.
13. Messina E.S., Tyndale R.F., Sellers E.M. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics 1997, 282:1608-1614.
14. Nunoya K.I., Yokoi T., Kimura K., Kainuma T., Satoh K., Kinoshita M., Kamataki T. A new CYP2A6 gene deletion responsible for the in vivo polymorphic metabolism of (+)-cis-3, 5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride in humans. Journal of Pharmacology and Experimental Therapeutics 1999, 289:437-442.
15. Nowell S., Sweeney C., Hammons G., Kadlubar F.F., Lang N.P. CYP2A6 activity determined by caffeine phenotyping: association with colorectal cancer risk. Cancer Epidemiology, Biomarkers & Prevention 2002, 11:377-383.
16. Shen J.J., Lin C.J., Huang J.L., Hsieh K.H., Kuo M.L. The effect of Liu-Wei-Di-Huang Wan on cytokine gene expression from human peripheral blood lymphocytes. American Journal of Chinese Medicine 2003, 31:247-257.
17. Sinclair P.R., Gorman N., Tsyrlov I.B., Fuhr U., Walton H.S., Sinclair J.F. Uroporphyrinogen oxidation catalyzed by human cytochromes P450. Drug Metabolism and Disposition 1998, 26:1019-1025.
18. Sweeney C., Coles B.F., Nowell S., Lang N.P., Kadlubar F.F. Novel markers of susceptibility to carcinogens in diet: associations with colorectal cancer. Toxicology 2002, 181-182:83-87.
19. Wu C.R., Lin L.W., Wang W.H., Hsieh M.T. The ameliorating effects of Liu Wei Di Huang Wan on cycloheximide-induced impairment of passive avoidance performance in rats. Journal of Ethnopharmacology 2007, 113:79-84.
20. Wu Y.C., Hsu J.H., Liu I.M., Liou S.S., Su H.C., Cheng J.T. Increase of insulin sensitivity in diabetic rats received Die-Huang-Wan, a herbal mixture used in Chinese traditional medicine. Acta Pharmacologica Sinica 2002, 23:1181-1187.
21. Zheng Y. The therapeutic effects of rehmannia oral liquid for the syndrome of heat accumulation with Yin consumption in esophagus cancer patients undergoing radiotherapy - a report of 60 cases. Journal of Traditional Chinese Medicine 2007, 27:248-254.
22. Zhou S., Gao Y., Jiang W., Huang M., Xu A., Paxton J.W. Interactions of herbs with cytochrome P450. Drug Metabolism Reviews 2003, 35:35-98.